Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05911321 · ClinicalTrials.gov registry record · Phase 2

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

A Phase 2 study of Multiple Myeloma and Aging, sponsored by UNC Lineberger Comprehensive Cancer Center.

Active
Registry status
Phase 2
Development phase
6
Enrollment target
2
Study locations

NCT05911321 is a Phase 2 study of Multiple Myeloma and Aging that is active but no longer recruiting, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 6 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05911321, a Phase 2 study of Multiple Myeloma and Aging, is active but no longer recruiting, sponsored by UNC Lineberger Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
6 participants
Enrollment target
2
Study locations

Study Summary

This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting has not been approved by the Food and Drug Administration (FDA).

Conditions Studied

Multiple Myeloma Aging Relapse Refractory Co-morbidity

Interventions

  • DRUG Dexamethasone
  • DRUG Pomalidomide
  • DRUG Isatuximab

Study Locations (2)

North Carolina

  • Lineberger Comprehensive Cancer Center - Chapel Hill
  • Atrium Health Wake Forest Baptist Medical Center - Winston-Salem

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2023-12-05
Est. Completion 2028-03-26
Phase Phase 2

Sponsor

UNC Lineberger Comprehensive Cancer Center

366 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05911321

The ClinicalTrials.gov registry entry for NCT05911321 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (99% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT05911321 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05911321 about?

NCT05911321 is a clinical study titled "Isa-Pom-Dex in Elderly/Frail Subjects With RRMM". This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment...

What is the current status of trial NCT05911321?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2023-12-05. Estimated completion is 2028-03-26.

What conditions does trial NCT05911321 study?

This clinical trial studies the following conditions: Multiple Myeloma, Aging, Relapse, Refractory, Co-morbidity.

What interventions are being tested in trial NCT05911321?

The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Isatuximab (DRUG).

Who is sponsoring clinical trial NCT05911321?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05911321 being conducted?

This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Aging

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.